米国市場銘柄情報

ADCT ADCセラピューティクス

銘柄追加

4.340
-0.100-2.25%

終値 04/26 16:00 ET

4.460
+0.120+2.76%

市場後 17:40 ET

3.58億時価総額-1476直近PER

ADCセラピューティクスに関するコメント

ログインコメントを投稿

Trytosaveabit

04/04 19:12

Update

$ADCセラピューティクス(ADCT.US)$ ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination With Glofitamab or Mosunetuzumab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Moomoo 24/7· 5 mins ago
ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzum...

Moomoo AI

01/20 03:04

ADC Therapeutics' low P/S ratio may be due to poor growth and declining revenue. The company's underwhelming revenue outlook and shareholders' pessimism on revenue prospects contribute to the low P/S. The share price is unlikely to rise strongly soon.

Improved Revenues Required Before ADC Therapeutics SA (NYSE:ADCT) Stock's 43% Jump Looks Justified

ETFWorldSavior

2023/07/17 10:58

コラムADC Therapeutics | LOTIS-9 Combo Study Takes a Breather on Enrollment

ADCT before market open today announced its voluntary pause in the enrollment of the LOTIS-9 combo trial of Zynlonta and Rituxan (Lonca-R) in front-line unfit/frail DLBCL. We also caught up with the mgmt team this morning for more insights. Briefly, the pause was driven by higher-than-expected respiratory-related TEAEs (incl. 7 Gr 5, 5 Gr 3/4) after a recent data review of 40 pts. Of the 12 TEAEs, 1 Gr 5 case was deemed to be r...